 |
 |
 |
 |
 |
 |
 |
 |
Potentia is an early stage biotechnology company focused on developing innovative therapeutics, primarily in the area of age-related macular degeneration and other inflammatory ocular diseases. Potentia assembles its pipeline of anti-inflammatory products through a combination of in-licensing of preclinical compounds and in-house research and development.
The safety of Potentia's POT-4, a small cyclic synthetic peptide, is being confirmed by the ASaP Phase I clinical trial conducted wet AMD patients.
The trial is ongoing at 6 sites across the United State.
more info on POT-4 »
- September 2008 Potentia Pharmaceuticals SSto present ASaP clinical trial data during the AAO annual meeting
more » - September 2008 Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4
more » - September 2008 Potentia featured in BioWorld article "The eye have it"
more » - September 2008 Potentia Poises for Validation in Complement Inhibition in AMD
more »
